Next 10 |
home / stock / gcvrz / gcvrz news
2024-04-12 12:02:53 ET More on AbbVie, Biogen, etc. AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67% Novo Nordisk: The Moat Won't Last Forever AbbVie: Still Fits Buffett's 10x EBT Rule Well Despite Guidance Revision No link between weight...
2024-04-12 07:05:43 ET More on Eli Lilly, Novo Nordisk, etc. Novo Nordisk: The Moat Won't Last Forever Eli Lilly: Three Threats To Its Huge Rally Why Eli Lilly And Rival Novo Nordisk Won't Be Troubled By Viking's Latest Weight Loss Data Roche, Eli Lilly gain ...
2024-04-09 14:15:55 ET More on Nurix, Sanofi, etc. Sanofi: My Top Pick In Big Pharma Sanofi (SNY) Barclays 26th Annual Global Healthcare Conference (Transcript) Sanofi (SNY) Leerink Partners Global Biopharma Conference (Transcript) Sanofi agrees to settle ~4K...
2024-04-04 08:20:35 ET More on CureVac BV CureVac: No Momentum In Sight Seeking Alpha’s Quant Rating on CureVac BV Historical earnings data for CureVac BV Financial information for CureVac BV Read the full article on Seeking Alpha For f...
2024-03-30 10:50:43 ET More on GSK, Pfizer, etc. Sanofi: My Top Pick In Big Pharma Pfizer: Attractive Valuation And A Strong Pipeline Mitigate Patent Cliff Concerns Sanofi (SNY) Barclays 26th Annual Global Healthcare Conference (Transcript) Pfizer, Astellas f...
2024-03-07 13:29:15 ET More on AstraZeneca, CSL, etc. Sanofi (SNY) TD Cowen 44th Annual Health Care Conference (Transcript) GSK Plc: An Undervalued Vaccine Behemoth That Is Resuming Growth; Buy CSL Limited: Earnings Beat Doesn't Mask Unfavorable Trial Results (Downgr...
2024-03-05 13:28:08 ET Summary Apogee Therapeutics' APG777 shows promising Phase 1 results for AD, with a notably long half-life potentially reducing dosing frequency. APG777's efficacy and safety profiles justify Phase 2 trials, aiming to outperform competitors like Sanofi's Dupi...
2024-02-21 07:13:01 ET Regeneron ( NASDAQ: REGN ) and Vertex Pharmaceuticals ( NASDAQ: VRTX ) have crossed $100B in market capitalization for the first time, joining two other giants in the biotech industry, Amgen ( AMGN ) and AbbVie ( ABBV ).... Read the full ...
2024-02-16 10:05:39 ET More on Denali, Sanofi, etc. Sanofi (SNY) Q4 2023 Earnings Call Transcript Sanofi 2023 Q4 - Results - Earnings Call Presentation Sanofi Expands Rare Disease Focus With Inhibrx's INBRX-101 Acquisition Sanofi, Regeneron win Japan approval...
2024-02-08 07:09:07 ET More on AstraZeneca AstraZeneca's Q4 Earnings: Recognizing The Underrated Gem's Growth Why AstraZeneca's Gracell Biotechnologies Acquisition Is A Win-Win AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition AstraZeneca beats t...
News, Short Squeeze, Breakout and More Instantly...
Sanofi Contingent Value Right (Expiring 12/31/2020) Company Name:
GCVRZ Stock Symbol:
NASDAQ Market:
* The British Pharmacological Society awards Cablivi® (caplacizumab), the first new treatment in 30 years for acquired Thrombotic Thrombocytopenic Purpura (aTTP), Drug Discovery of the Year 2020 * TTP is a rare blood clotting disorder with 330 people known to be affected i...